ERBB2 and neoplasm: To date, CAR T cells have been reported to target a number of antigens on tumour cells including CD33 43, CD19 44,45, carboxy-anhydrase-IX 46, CD20 47, ERBB2-Her2/neu 48,49, GD2 50,51, PSMA 52,53, PSCA 54,55, mesothelin 56, CD171 57, VEGF-R2 58, MUC-16 59 and folate receptor-α 60,61.